Loading…
Alnylam Pharmaceuticals, Inc. is projected to rise to $390.25 by 2027, a +32% move from its current price of $295.63. ALNY is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $291.22 | $295.88 | $300.60 | +0.08% |
| May 30 | $289.56 | $296.12 | $302.84 | +0.17% |
| May 31 | $288.35 | $296.37 | $304.62 | +0.25% |
| Jun 1 | $287.36 | $296.62 | $306.17 | +0.33% |
| Jun 2 | $286.53 | $296.87 | $307.58 | +0.42% |
| Jun 3 | $285.80 | $297.11 | $308.88 | +0.50% |
| Jun 4 | $285.15 | $297.36 | $310.10 | +0.59% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $285.15 | $297.36 | $310.10 | +0.59% |
| Week 2 | $281.88 | $299.11 | $317.38 | +1.18% |
| Week 3 | $279.78 | $300.86 | $323.53 | +1.77% |
| Week 4 | $278.28 | $302.62 | $329.10 | +2.37% |
| Week 5 | $277.15 | $304.40 | $334.32 | +2.97% |
| Week 6 | $276.29 | $306.18 | $339.30 | +3.57% |
| Week 7 | $275.64 | $307.98 | $344.11 | +4.18% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alnylam Pharmaceuticals, Inc. is a healthcare company that discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, it develops a range of products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers.
The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam Pharmaceuticals, Inc. (ALNY) is a healthcare company with a current share price of $297.45 and a market capitalization of $39.71B. It is ranked 366 in market capitalization.
A major floor 13.4% below — a decisive break under it would weaken the trend.
The nearest floor, 3.6% below — buyers have tended to step in here.
The nearest ceiling, 12.8% above — a clean break opens room to run.
A major ceiling 25.2% above — clearing it would confirm fresh momentum.
Key ALNY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALNY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $297.51 | Sell | $295.93 | Sell |
| MA 10 | $294.01 | Buy | $295.58 | Buy |
| MA 20 | $295.84 | Sell | $297.95 | Sell |
| MA 50 | $309.49 | Sell | $309.26 | Sell |
| MA 100 | $327.38 | Sell | $329.36 | Sell |
| MA 200 | $386.93 | Sell | $344.01 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.67 | Neutral |
| Stoch RSI (14) | 75.91 | Neutral |
| CCI (20) | -3.20 | Neutral |
| Williams %R (14) | -31.14 | Info |
| MACD (12,26,9) | 1.39 | Buy |
| ROC (12) | 0.20 | Buy |
| Bollinger %B (20,2) | 0.49 | Neutral |
| Stochastic %K (14) | 68.86 | Neutral |
| TRIX (15) | -0.28 | Sell |
| Awesome (5,34) | -7.06 | Sell |
| Ultimate (7,14,28) | 58.92 | Neutral |
| Momentum (10) | 3.60 | Buy |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 298.69 | Sell |
| ADX (14) | 14.05 | Neutral |
| ATR (14) | 4.21 | Info |
Technically, the 30-day picture is NEUTRAL. The RSI(14) is 50, and the stock’s price remains below the SMA50 of $310.32 while well below the SMA200 of $388.35. The immediate support is at $284.84 and resistance at $339.41. The 30-day price range runs from $266.28 to $332.27, and the stock shows an annualized volatility of 30%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $284.84 | $295.63 | $430.30 | 0% | Neutral | |
| $318.80 | $390.25 | $500.02 | +32% | Bullish | |
| $357.13 | $445.14 | $585.25 | +51% | Bullish | |
| $367.15 | $464.56 | $623.50 | +57% | Bullish | |
| $372.71 | $477.88 | $652.72 | +62% | Bullish | |
| $410.23 | $532.34 | $738.44 | +80% | Bullish | |
| $450.02 | $590.51 | $830.66 | +100% | Bullish | |
| $527.94 | $700.00 | $997.28 | +137% | Bullish | |
| $571.43 | $765.15 | $1,103.02 | +159% | Bullish | |
| $550.52 | $744.09 | $1,084.50 | +152% | Bullish | |
| $826.57 | $1,165.04 | $1,778.91 | +294% | Bullish | |
| $1,314.05 | $1,986.08 | $3,249.76 | +572% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $284.84 | $295.63 | $345.99 | +0.00% |
| June 2026 | $261.29 | $304.81 | $362.48 | +3.11% |
| July 2026 | $271.91 | $319.02 | $382.97 | +4.66% |
| August 2026 | $274.77 | $323.84 | $391.57 | +1.51% |
| September 2026 | $278.30 | $329.22 | $400.44 | +1.66% |
| October 2026 | $289.43 | $343.54 | $420.12 | +4.35% |
| November 2026 | $294.88 | $351.06 | $431.34 | +2.19% |
| December 2026 | $292.02 | $348.66 | $430.30 | -0.68% |
Click any year to see its month-by-month ALNY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ALNY to range from $284.84 to $430.30 through 2026. The $295.63 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ALNY price prediction for 2027 points to an average of $390.25 (low $318.80, high $500.02) — a potential gain of +32% on today's $295.63. Momentum favours further upside here.
In 2028, ALNY is projected to trade between $357.13 and $585.25, averaging $445.14 — a potential gain of +51% from today's $295.63. That is up +14% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Alnylam Pharmaceuticals, Inc.'s 2029 outlook centres on $464.56, within a $367.15 to $623.50 range. That is up +4% on the projected 2028 average. That marks a +57% change versus current levels. Momentum favours further upside here.
By 2030, ALNY could reach as high as $652.72, with a base case around $477.88 and support toward $372.71 — roughly +62% from $295.63. Buyers look set to stay in control over this stretch.
Expect ALNY to range from $410.23 to $738.44 through 2031. The $532.34 average target implies a +80% move from current prices. That is up +11% on the projected 2030 average. Momentum favours further upside here.
The ALNY price prediction for 2032 points to an average of $590.51 (low $450.02, high $830.66) — a potential gain of +100% on today's $295.63. Buyers look set to stay in control over this stretch.
In 2033, ALNY is projected to trade between $527.94 and $997.28, averaging $700.00 — a potential gain of +137% from today's $295.63. That is up +19% on the projected 2032 average. Momentum favours further upside here.
Alnylam Pharmaceuticals, Inc.'s 2034 outlook centres on $765.15, within a $571.43 to $1,103.02 range. That is up +9% on the projected 2033 average. That marks a +159% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ALNY could reach as high as $1,084.50, with a base case around $744.09 and support toward $550.52 — roughly +152% from $295.63. Momentum favours further upside here.
Expect ALNY to range from $826.57 to $1,778.91 through 2040. The $1,165.04 average target implies a +294% move from current prices. That is up +57% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ALNY price prediction for 2050 points to an average of $1,986.08 (low $1,314.05, high $3,249.76) — a potential gain of +572% on today's $295.63. Momentum favours further upside here.
Investing $1,000 in ALNY today (≈ 3.382607 ALNY) could be worth
$6,718.13
+$5,718.13 (+572%) by 2050 · US Dollar
Based on the average projected ALNY price of $1,986.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALNYwould be worth at today's price.
$1,000 invested in ALNY on May 27, 2025 (≈ 3.447087 ALNY) would be worth
$1,019.06
+$19.06 (+1.9%) today · 1.02× · US Dollar
Based on a ALNY entry price of $290.1 vs. today's $295.63.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $298.48 | $990.45 | -1.0% |
| 1 month ago | $308.51 | $958.25 | -4.2% |
| 3 months ago | $331.24 | $892.49 | -10.8% |
| 6 months ago | $451.23 | $655.16 | -34.5% |
| 1 year ago | $290.1 | $1,019.06 | +1.9% |
| All time (5.0y) ago | $144.28 | $2,049 | +104.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALNY forecast.
Our base-case forecast reaches $590.00 around 2032.
Implied market cap at $590.00: $78.77B
The multi-year forecast paints a bullish path, with the average price rising from $297.45 in 2026 to higher levels in coming decades. In 2030 the average is projected at $478.25 with a 60.8% ROI, and by 2040 the average climbs to $1,150.88 with a 286.9% ROI, followed by a 2050 average of $1,952.17 and a 556.3% ROI. These figures illustrate a strong, extended upside despite the 2026 baseline showing 0% ROI.
Overall, the long horizon remains bullish, with substantial upside implied by 2040 and 2050, while recognizing that these are estimates and not guarantees of future results.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $478.25, with a minimum of $372.93 and a maximum of $653.39, and a 60.8% ROI. The sentiment is BULLISH.
Forecasts from 2027 onward show bullish sentiment, with 2027 average $393.68 (ROI 32.4%), 2028 average $445.48 (ROI 49.8%), 2029 average $464.21 (ROI 56.1%), 2031 average $529.46 (ROI 78%), 2032 average $588.31 (ROI 97.8%), 2033 average $697.95 (ROI 134.6%), 2040 average $1,150.88 (ROI 286.9%), and 2050 average $1,952.17 (ROI 556.3%). These are estimates and not guarantees.
Yes. The 2040 forecast shows a max of $1,757.49 and an average of $1,150.88, with a minimum of $816.43, implying that reaching $1,000 is within the forecast range.
Current price is $297.45 and market cap is $39.71B.
RSI(14) is 50 with NEUTRAL sentiment. The price is below the SMA50 of $310.32 and below the SMA200 of $388.35. The 30-day range is $266.28–$332.27, with support at $284.84 and resistance at $339.41; volatility is 30%.
Alnylam Pharmaceuticals, Inc. Community Discussion
0Share your Alnylam Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.